Cellectis S.A.CLLSEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
CLLS Q2 2024 Key Financial Metrics
Revenue
$9.5M
Gross Profit
N/A
Operating Profit
$-17.2M
Net Profit
$-25.3M
Gross Margin
N/A
Operating Margin
-181.1%
Net Margin
-265.9%
YoY Growth
375.0%
EPS
$-0.28
Financial Flow
Cellectis S.A. Q2 2024 Financial Summary
Cellectis S.A. reported revenue of $9.5M (up 375.0% YoY) for Q2 2024, with a net profit of $-25.3M (down 51.9% YoY) (-265.9% margin). Cost of goods sold was N/A.
Key Financial Metrics
| Total Revenue | $9.5M |
|---|---|
| Net Profit | $-25.3M |
| Gross Margin | N/A |
| Operating Margin | -181.1% |
| Report Period | Q2 2024 |
Cellectis S.A. Quarterly Revenue & Net Profit History
Cellectis S.A. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 2024 | $9.5M | +375.0% | $-25.3M | -265.9% |
| Q3 2023 | $1.6M | — | $-17.5M | -1064.1% |
| Q2 2023 | $2.0M | -26.5% | $-16.6M | -831.6% |
| Q2 2022 | $2.7M | -81.4% | $-19.5M | -714.4% |
Income Statement
| Q2 2022 | Q2 2023 | Q3 2023 | Q2 2024 | |
|---|---|---|---|---|
| Revenue | $2.7M | $2.0M | $1.6M | $9.5M |
| YoY Growth | -81.4% | -26.5% | N/A | 375.0% |
Balance Sheet
| Q2 2022 | Q2 2023 | Q3 2023 | Q2 2024 | |
|---|---|---|---|---|
| Assets | $320.9M | $227.7M | $209.7M | $407.1M |
| Liabilities | $140.4M | $131.1M | $133.6M | $258.5M |
| Equity | $180.5M | $96.6M | $76.1M | $148.6M |
Cash Flow
| Q2 2022 | Q2 2023 | Q2 2024 | |
|---|---|---|---|
| Operating CF | $-60.2M | $-47.4M | $28.9M |